NATCAPSUQNatural Capsules Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Natural Capsules Limited engages in the manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally. The company offers bovine spongiform encephalopathy and transmissible spongiform encephalopathy-free gelatin, shiny gelatin, sodium lauryl sulfate-free gelatin, halal-certified gelatin, fast-release gelatin, printed gelatin/cellulose, vegetarian, and enteric capsule shells. It is also involved in formulating pharmaceutical dosage forms in capsule dosage form. Natural Capsules Limited was incorporated in 1993 and is based in Bengaluru, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Risk gate: safety score is only 10/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • Revenue growth: 7.8% YoY
- • Profit growth: -4077.4% YoY
- • MACD: bearish
- • Volume: 0.2x 20-day average
⚖️ 3 bullish pattern setups are currently active on this stock. Pattern setup-quality percentages measure how cleanly a chart formation developed — they are not an endorsement of the company. Short-term traders may still trade those setups with strict stops; the AVOID verdict reflects the overall risk/fundamental profile for holding.
Bull case
- • Debt/Equity: 0.49
- • Promoter holding: 65.3%
- • RSI: 53
- • Price vs EMA21: above
Bear case
- • Revenue growth: 7.8% YoY
- • Profit growth: -4077.4% YoY
- • MACD: bearish
- • Volume: 0.2x 20-day average
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: 7.8% YoY
- • Profit growth: -4077.4% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹12.55). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.